<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03384745</url>
  </required_header>
  <id_info>
    <org_study_id>AV002</org_study_id>
    <nct_id>NCT03384745</nct_id>
  </id_info>
  <brief_title>A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis</brief_title>
  <official_title>A Phase 2b Randomized, Double-blind, Placebo Controlled, Multi-center 12-week Study With an Additional 40-week Follow-up Assessment of Efficacy, Safety and Tolerability of M1095 in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bond Avillion 2 Development LP</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Avillion LLP</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bond Avillion 2 Development LP</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center phase 2b study in subjects with moderate to severe chronic plaque-type&#xD;
      psoriasis. Approximately 300 subjects will be enrolled at approximately 60 investigator sites&#xD;
      in North America and Europe.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 31, 2018</start_date>
  <completion_date type="Actual">March 26, 2020</completion_date>
  <primary_completion_date type="Actual">June 20, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With an Investigator's Global Assessment (IGA) Score of 0 or 1</measure>
    <time_frame>Week 12, as compared to Week 0 (baseline)</time_frame>
    <description>The primary endpoint is achievement of an IGA score of 0 or 1 at Week 12, with an IGA reduction of at least 2 points from baseline. The percentage of subjects in the Intent to Treat (ITT) Analysis Set with an IGA score of 0 or 1 at Week 12 will be used to compare treatment arms. IGA is the Investigator's Global Assessment of the extent of psoriasis, with 0 = clear of psoriasis, 1 = almost clear, 2 = mild psoriasis, 3 = moderate psoriasis, and 4 = severe psoriasis (the worst assessment on this scale). Higher scores in the IGA indicate a worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Psoriasis Area and Severity Index (PASI) Reduction of 100% (i.e. Clear of Psoriasis)</measure>
    <time_frame>Week 12, as compared to Week 0 (baseline)</time_frame>
    <description>PASI 100, i.e. a subject's psoriasis has completely cleared at Week 12, compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Psoriasis Area and Severity Index (PASI) Reduction of 90% (i.e. a 90% Improvement in Psoriasis)</measure>
    <time_frame>Week 12, as compared to baseline</time_frame>
    <description>PASI 90, i.e. a subject's psoriasis has cleared by 90% at Week 12, compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Psoriasis Area and Severity Index (PASI) Reduction of 75% (i.e. a 75% Improvement in Psoriasis)</measure>
    <time_frame>Week 12, as compared to Week 0 (baseline)</time_frame>
    <description>PASI 75, i.e. a subject's psoriasis has cleared by 75% at Week 12, compared to baseline</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">313</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>M1095 (Sonelokimab) 30mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>M1095, 30 mg, given at Week 0, 2, 4, 8, 12 and every four weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>M1095 (Sonelokimab) 60mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>M1095, 60 mg, given at Week 0, 2, 4, 8, 12 and every four weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>M1095 (Sonelokimab) 120mg - regimen 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>M1095, 120 mg, given at Week 0, 2, 4, 8, 12 and every eight weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>M1095 (Sonelokimab) 120mg - regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>M1095, 120 mg, given at Week 0, 2, 4, 6, 8, 10, 12 and every four weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo / M1095 (Sonelokimab) 120mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, given at Week 0, 1, 2, 3, 4, 6, 8 and 10, then M1095, 120mg, given at Week 12, 14, 16, and every four weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Secukinumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Secukinumab, 300mg, given at Week 0, 1, 2, 3, 4, 8, 12 and every four weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M1095 (Sonelokimab)</intervention_name>
    <description>M1095 (Sonelokimab) is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.</description>
    <arm_group_label>M1095 (Sonelokimab) 120mg - regimen 1</arm_group_label>
    <arm_group_label>M1095 (Sonelokimab) 120mg - regimen 2</arm_group_label>
    <arm_group_label>M1095 (Sonelokimab) 30mg</arm_group_label>
    <arm_group_label>M1095 (Sonelokimab) 60mg</arm_group_label>
    <arm_group_label>Placebo / M1095 (Sonelokimab) 120mg</arm_group_label>
    <other_name>Sonelokimab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo contains no active drug.</description>
    <arm_group_label>Placebo / M1095 (Sonelokimab) 120mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Secukinumab</intervention_name>
    <description>Secukinumab is a human immunoglobulin G1 (IgG1) monoclonal antibody that selectively binds IL-17A.</description>
    <arm_group_label>Secukinumab</arm_group_label>
    <other_name>Cosentyx®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female subjects between 18 and 75 years of age.&#xD;
&#xD;
          2. Moderate to severe plaque-type psoriasis for at least 6 months.&#xD;
&#xD;
          3. Subject is a candidate for systemic biologic therapy.&#xD;
&#xD;
          4. Subject has IGA ≥3, involved body surface area (BSA) ≥10%, and PASI ≥12 at screening&#xD;
             and at baseline.&#xD;
&#xD;
          5. Subject is able to comply with the study procedures.&#xD;
&#xD;
          6. Subject must provide informed consent.&#xD;
&#xD;
        Exclusion Criteria (Main):&#xD;
&#xD;
          1. Non-plaque type psoriasis, drug-induced psoriasis, or other skin conditions (e.g.,&#xD;
             eczema). (Psoriatic arthritis is allowed).&#xD;
&#xD;
          2. Other medical conditions, including planned surgery or active infection / history of&#xD;
             infection, as defined in the study protocol. Subjects will be screened for&#xD;
             tuberculosis and hepatitis B / hepatitis C.&#xD;
&#xD;
          3. Laboratory abnormalities at screening, as defined in the study protocol.&#xD;
&#xD;
          4. Prior use of systemic or topical treatments for psoriasis, as defined in the study&#xD;
             protocol.&#xD;
&#xD;
          5. Prior use of any compound targeting IL-17, more than two biologic therapies,&#xD;
             ustekinumab within 6 months, or TNF targeting therapies within 12 weeks.&#xD;
&#xD;
          6. History of suicidal thoughts within 12 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Kim Papp</last_name>
    <role>Principal Investigator</role>
    <affiliation>Probity Medical Research Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Bexley</city>
        <state>Ohio</state>
        <zip>43209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Dupnitsa</city>
        <zip>2600</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5K 1X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3R 6A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V 0C6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>North Bay</city>
        <state>Ontario</state>
        <zip>P1B 3Z7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6J 7W5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K2G 6E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Richmond Hill</city>
        <state>Ontario</state>
        <zip>L4B 1A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 1E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1V 4X7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Brno</city>
        <zip>602 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Nový Jičín</city>
        <zip>741 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Náchod</city>
        <zip>547 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Ostrava</city>
        <zip>702 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Ostrava</city>
        <zip>708 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Pardubice</city>
        <zip>530 02</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Praha</city>
        <zip>130 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Uherské Hradiště</city>
        <zip>686 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Augsburg</city>
        <zip>86179</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10789</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Bochum</city>
        <zip>44793</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Darmstadt</city>
        <zip>64297</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Frankfurt/Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Friedrichshafen</city>
        <zip>88045</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20354</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Mahlow</city>
        <zip>15831</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Osnabrück</city>
        <zip>49074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Quedlinburg</city>
        <zip>06484</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Schwerin</city>
        <zip>19055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1085</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1135</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Kecskemét</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Orosháza</city>
        <zip>5900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Szolnok</city>
        <zip>5000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-060</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-314</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Poznań</city>
        <zip>60-848</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Siedlce</city>
        <zip>08-110</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Skierniewice</city>
        <zip>96-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-777</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>04-141</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Papp KA, Weinberg MA, Morris A, Reich K. IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study. Lancet. 2021 Apr 24;397(10284):1564-1575. doi: 10.1016/S0140-6736(21)00440-2. Erratum in: Lancet. 2021 Jun 5;397(10290):2150.</citation>
    <PMID>33894834</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 20, 2017</study_first_submitted>
  <study_first_submitted_qc>December 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 27, 2017</study_first_posted>
  <results_first_submitted>April 1, 2021</results_first_submitted>
  <results_first_submitted_qc>July 9, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 2, 2021</results_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 16, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT03384745/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 24, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT03384745/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were adults aged 18-75 years with stable, moderate to severe plaque type psoriasis for &gt;6 months prior to randomisation, and who were candidates for systemic biologic therapy.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>M1095 30mg</title>
          <description>M1095, 30 mg, given at Week 0, 2, 4, 8, 12 and every four weeks.&#xD;
Subjects with IGA&gt;1 at Week 12 were escalated to receive M1095, 120mg&#xD;
M1095: M1095 is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.</description>
        </group>
        <group group_id="P2">
          <title>M1095 60mg</title>
          <description>M1095, 60 mg, given at Week 0, 2, 4, 8, 12 and every four weeks.&#xD;
Subjects with IGA&gt;1 at Week 12 were escalated to receive M1095, 120mg&#xD;
M1095: M1095 is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.</description>
        </group>
        <group group_id="P3">
          <title>M1095 120mg - Regimen 1</title>
          <description>M1095, 120 mg, given at Week 0, 2, 4, 8, 12 and every eight weeks.&#xD;
M1095: M1095 is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.</description>
        </group>
        <group group_id="P4">
          <title>M1095 120mg - Regimen 2</title>
          <description>M1095, 120 mg, given at Week 0, 2, 4, 6, 8, 10, 12 and every four weeks.&#xD;
M1095: M1095 is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.</description>
        </group>
        <group group_id="P5">
          <title>Placebo / M1095 120mg</title>
          <description>Placebo, given at Week 0, 1, 2, 3, 4, 6, 8 and 10, then M1095, 120mg, given at Week 12, 14, 16, and every four weeks.&#xD;
M1095: M1095 is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.&#xD;
Placebo: Placebo contains no active drug.</description>
        </group>
        <group group_id="P6">
          <title>Secukinumab</title>
          <description>Secukinumab, 300mg, given at Week 0, 1, 2, 3, 4, 8, 12 and every four weeks.&#xD;
Secukinumab: Secukinumab is a human immunoglobulin G1 (IgG1) monoclonal antibody that selectively binds IL-17A.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Placebo Controlled Induction (W0 - W12)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="53"/>
                <participants group_id="P4" count="51"/>
                <participants group_id="P5" count="52"/>
                <participants group_id="P6" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="50"/>
                <participants group_id="P4" count="49"/>
                <participants group_id="P5" count="49"/>
                <participants group_id="P6" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Maintenance/Escalation (W12-W24)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="50"/>
                <participants group_id="P4" count="49"/>
                <participants group_id="P5" count="49"/>
                <participants group_id="P6" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="49"/>
                <participants group_id="P4" count="47"/>
                <participants group_id="P5" count="47"/>
                <participants group_id="P6" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Response Assess/Dose Hold (W24-W48)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="49"/>
                <participants group_id="P4" count="47"/>
                <participants group_id="P5" count="47"/>
                <participants group_id="P6" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="45"/>
                <participants group_id="P4" count="43"/>
                <participants group_id="P5" count="46"/>
                <participants group_id="P6" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>M1095 30mg</title>
          <description>M1095, 30 mg, given at Week 0, 2, 4, 8, 12 and every four weeks.&#xD;
M1095: M1095 is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.</description>
        </group>
        <group group_id="B2">
          <title>M1095 60mg</title>
          <description>M1095, 60 mg, given at Week 0, 2, 4, 8, 12 and every four weeks.&#xD;
M1095: M1095 is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.</description>
        </group>
        <group group_id="B3">
          <title>M1095 120mg - Regimen 1</title>
          <description>M1095, 120 mg, given at Week 0, 2, 4, 8, 12 and every eight weeks.&#xD;
M1095: M1095 is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.</description>
        </group>
        <group group_id="B4">
          <title>M1095 120mg - Regimen 2</title>
          <description>M1095, 120 mg, given at Week 0, 2, 4, 6, 8, 10, 12 and every four weeks.&#xD;
M1095: M1095 is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.</description>
        </group>
        <group group_id="B5">
          <title>Placebo / M1095 120mg</title>
          <description>Placebo, given at Week 0, 1, 2, 3, 4, 6, 8 and 10, then M1095, 120mg, given at Week 12, 14, 16, and every four weeks.&#xD;
M1095: M1095 is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.&#xD;
Placebo: Placebo contains no active drug.</description>
        </group>
        <group group_id="B6">
          <title>Secukinumab</title>
          <description>Secukinumab, 300mg, given at Week 0, 1, 2, 3, 4, 8, 12 and every four weeks.&#xD;
Secukinumab: Secukinumab is a human immunoglobulin G1 (IgG1) monoclonal antibody that selectively binds IL-17A.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="52"/>
            <count group_id="B2" value="52"/>
            <count group_id="B3" value="53"/>
            <count group_id="B4" value="51"/>
            <count group_id="B5" value="52"/>
            <count group_id="B6" value="53"/>
            <count group_id="B7" value="313"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="53"/>
                    <count group_id="B4" value="51"/>
                    <count group_id="B5" value="52"/>
                    <count group_id="B6" value="53"/>
                    <count group_id="B7" value="313"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.2" spread="13.4"/>
                    <measurement group_id="B2" value="46.9" spread="12.3"/>
                    <measurement group_id="B3" value="44.1" spread="13.1"/>
                    <measurement group_id="B4" value="43.2" spread="13.2"/>
                    <measurement group_id="B5" value="45.9" spread="12.9"/>
                    <measurement group_id="B6" value="47.5" spread="13.8"/>
                    <measurement group_id="B7" value="46.0" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="53"/>
                    <count group_id="B4" value="51"/>
                    <count group_id="B5" value="52"/>
                    <count group_id="B6" value="53"/>
                    <count group_id="B7" value="313"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="34"/>
                    <measurement group_id="B5" value="39"/>
                    <measurement group_id="B6" value="38"/>
                    <measurement group_id="B7" value="228"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="15"/>
                    <measurement group_id="B7" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="53"/>
                    <count group_id="B4" value="51"/>
                    <count group_id="B5" value="52"/>
                    <count group_id="B6" value="53"/>
                    <count group_id="B7" value="313"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="51"/>
                    <measurement group_id="B6" value="51"/>
                    <measurement group_id="B7" value="298"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="53"/>
                    <count group_id="B4" value="51"/>
                    <count group_id="B5" value="52"/>
                    <count group_id="B6" value="53"/>
                    <count group_id="B7" value="313"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="47"/>
                    <measurement group_id="B5" value="44"/>
                    <measurement group_id="B6" value="49"/>
                    <measurement group_id="B7" value="282"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="53"/>
                    <count group_id="B4" value="51"/>
                    <count group_id="B5" value="52"/>
                    <count group_id="B6" value="53"/>
                    <count group_id="B7" value="313"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="11"/>
                    <measurement group_id="B7" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="53"/>
                    <count group_id="B4" value="51"/>
                    <count group_id="B5" value="52"/>
                    <count group_id="B6" value="53"/>
                    <count group_id="B7" value="313"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="53"/>
                    <count group_id="B4" value="51"/>
                    <count group_id="B5" value="52"/>
                    <count group_id="B6" value="53"/>
                    <count group_id="B7" value="313"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czechia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="53"/>
                    <count group_id="B4" value="51"/>
                    <count group_id="B5" value="52"/>
                    <count group_id="B6" value="53"/>
                    <count group_id="B7" value="313"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="16"/>
                    <measurement group_id="B7" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="53"/>
                    <count group_id="B4" value="51"/>
                    <count group_id="B5" value="52"/>
                    <count group_id="B6" value="53"/>
                    <count group_id="B7" value="313"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bulgaria</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="53"/>
                    <count group_id="B4" value="51"/>
                    <count group_id="B5" value="52"/>
                    <count group_id="B6" value="53"/>
                    <count group_id="B7" value="313"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="53"/>
                    <count group_id="B4" value="51"/>
                    <count group_id="B5" value="52"/>
                    <count group_id="B6" value="53"/>
                    <count group_id="B7" value="313"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height (cm)</title>
          <population>Height was not captured for one subject at baseline.</population>
          <units>centimetres</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="53"/>
                    <count group_id="B4" value="50"/>
                    <count group_id="B5" value="52"/>
                    <count group_id="B6" value="53"/>
                    <count group_id="B7" value="312"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="173" spread="10.4"/>
                    <measurement group_id="B2" value="173" spread="9.60"/>
                    <measurement group_id="B3" value="174" spread="9.89"/>
                    <measurement group_id="B4" value="173" spread="11.2"/>
                    <measurement group_id="B5" value="173" spread="10.1"/>
                    <measurement group_id="B6" value="172" spread="9.98"/>
                    <measurement group_id="B7" value="173" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight at baseline (kg)</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="53"/>
                    <count group_id="B4" value="51"/>
                    <count group_id="B5" value="52"/>
                    <count group_id="B6" value="53"/>
                    <count group_id="B7" value="313"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92.0" spread="19.0"/>
                    <measurement group_id="B2" value="91.5" spread="20.6"/>
                    <measurement group_id="B3" value="89.0" spread="18.3"/>
                    <measurement group_id="B4" value="93.0" spread="22.6"/>
                    <measurement group_id="B5" value="91.3" spread="24.1"/>
                    <measurement group_id="B6" value="90.3" spread="22.4"/>
                    <measurement group_id="B7" value="91.2" spread="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior biological use (actual)</title>
          <description>Prior biological use included treatment with ustekinumab (stopping at least six months prior to randomization), tumour necrosis factor (TNF) targeting therapies (stopping at least 12 weeks prior to randomization), or investigational therapies (stopping at least 12 weeks, or 5 half lives, whichever is the longer, prior to randomization).&#xD;
Subjects treated with more than 2 biological therapies as above were excluded from the study.&#xD;
Subjects receiving prior treatment at any time with any compound (marketed or investigational) targeting interleukin-17 were excluded from the study.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="53"/>
                    <count group_id="B4" value="51"/>
                    <count group_id="B5" value="52"/>
                    <count group_id="B6" value="53"/>
                    <count group_id="B7" value="313"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="44"/>
                    <measurement group_id="B5" value="44"/>
                    <measurement group_id="B6" value="46"/>
                    <measurement group_id="B7" value="263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of psoriasis (years)</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="53"/>
                    <count group_id="B4" value="51"/>
                    <count group_id="B5" value="52"/>
                    <count group_id="B6" value="53"/>
                    <count group_id="B7" value="313"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.0" spread="13.6"/>
                    <measurement group_id="B2" value="19.7" spread="12.8"/>
                    <measurement group_id="B3" value="15.8" spread="12.9"/>
                    <measurement group_id="B4" value="18.0" spread="11.7"/>
                    <measurement group_id="B5" value="16.3" spread="12.1"/>
                    <measurement group_id="B6" value="20.2" spread="13.6"/>
                    <measurement group_id="B7" value="18.3" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Presence of psoriatic arthritis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="53"/>
                    <count group_id="B4" value="51"/>
                    <count group_id="B5" value="52"/>
                    <count group_id="B6" value="53"/>
                    <count group_id="B7" value="313"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="45"/>
                    <measurement group_id="B5" value="49"/>
                    <measurement group_id="B6" value="51"/>
                    <measurement group_id="B7" value="288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Investigator's Global Assessment (IGA) at baseline</title>
          <description>Investigator's Global Assessment is a rating scale for overall psoriatic disease. Assessment ranges from 0 (clear of psoriasis), 1 (almost clear), 2 (mild), 3 (moderate) or 4 (severe).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="53"/>
                    <count group_id="B4" value="51"/>
                    <count group_id="B5" value="52"/>
                    <count group_id="B6" value="53"/>
                    <count group_id="B7" value="313"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="41"/>
                    <measurement group_id="B6" value="38"/>
                    <measurement group_id="B7" value="233"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="15"/>
                    <measurement group_id="B7" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Psoriasis Area and Severity Index (PASI) at baseline</title>
          <description>The Psoriasis Area and Severity Index (PASI) combines assessments of the extent of body-surface area involvement in four anatomical regions (head, trunk, arms, legs) and the severity of desquamation, erythema and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72.0 for the most severe disease.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="53"/>
                    <count group_id="B4" value="51"/>
                    <count group_id="B5" value="52"/>
                    <count group_id="B6" value="53"/>
                    <count group_id="B7" value="313"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.3" spread="7.91"/>
                    <measurement group_id="B2" value="20.7" spread="9.34"/>
                    <measurement group_id="B3" value="21.1" spread="8.38"/>
                    <measurement group_id="B4" value="20.6" spread="7.15"/>
                    <measurement group_id="B5" value="20.5" spread="6.89"/>
                    <measurement group_id="B6" value="21.7" spread="8.80"/>
                    <measurement group_id="B7" value="20.8" spread="8.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Percentage of total Body Surface Area (BSA) affected at baseline</title>
          <description>The percentage of total Body Surface Area (BSA) affected by plaque-type psoriasis was estimated from the percentages of areas affected, including head, trunk, upper limbs and lower limbs.</description>
          <units>% of body surface area affected</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="52"/>
                    <count group_id="B2" value="52"/>
                    <count group_id="B3" value="53"/>
                    <count group_id="B4" value="51"/>
                    <count group_id="B5" value="52"/>
                    <count group_id="B6" value="53"/>
                    <count group_id="B7" value="313"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.0" spread="15.7"/>
                    <measurement group_id="B2" value="24.8" spread="15.6"/>
                    <measurement group_id="B3" value="25.3" spread="14.8"/>
                    <measurement group_id="B4" value="26.4" spread="12.8"/>
                    <measurement group_id="B5" value="26.2" spread="16.7"/>
                    <measurement group_id="B6" value="28.1" spread="16.1"/>
                    <measurement group_id="B7" value="26.1" spread="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With an Investigator's Global Assessment (IGA) Score of 0 or 1</title>
        <description>The primary endpoint is achievement of an IGA score of 0 or 1 at Week 12, with an IGA reduction of at least 2 points from baseline. The percentage of subjects in the Intent to Treat (ITT) Analysis Set with an IGA score of 0 or 1 at Week 12 will be used to compare treatment arms. IGA is the Investigator's Global Assessment of the extent of psoriasis, with 0 = clear of psoriasis, 1 = almost clear, 2 = mild psoriasis, 3 = moderate psoriasis, and 4 = severe psoriasis (the worst assessment on this scale). Higher scores in the IGA indicate a worse outcome.</description>
        <time_frame>Week 12, as compared to Week 0 (baseline)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>M1095 30mg</title>
            <description>M1095, 30 mg, given at Week 0, 2, 4, and 8 weeks.&#xD;
M1095: M1095 is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.</description>
          </group>
          <group group_id="O2">
            <title>M1095 60mg</title>
            <description>M1095, 60 mg, given at Week 0, 2, 4, and 8 weeks.&#xD;
M1095: M1095 is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.</description>
          </group>
          <group group_id="O3">
            <title>M1095 120mg - Normal Load Group</title>
            <description>M1095, 120 mg, given at Week 0, 2, 4, and 8 weeks.&#xD;
M1095: M1095 is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.</description>
          </group>
          <group group_id="O4">
            <title>M1095 120mg - Augmented Load Group</title>
            <description>M1095, 120 mg, given at Week 0, 2, 4, 6, 8, and 10 weeks.&#xD;
M1095: M1095 is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo, given at Week 0, 1, 2, 3, 4, 6, 8 and 10 weeks.&#xD;
Placebo: Placebo contains no active drug.</description>
          </group>
          <group group_id="O6">
            <title>Secukinumab</title>
            <description>Secukinumab, 300mg, given at Week 0, 1, 2, 3, 4, and 8 weeks.&#xD;
Secukinumab: Secukinumab is a human immunoglobulin G1 (IgG1) monoclonal antibody that selectively binds IL-17A.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Investigator's Global Assessment (IGA) Score of 0 or 1</title>
          <description>The primary endpoint is achievement of an IGA score of 0 or 1 at Week 12, with an IGA reduction of at least 2 points from baseline. The percentage of subjects in the Intent to Treat (ITT) Analysis Set with an IGA score of 0 or 1 at Week 12 will be used to compare treatment arms. IGA is the Investigator's Global Assessment of the extent of psoriasis, with 0 = clear of psoriasis, 1 = almost clear, 2 = mild psoriasis, 3 = moderate psoriasis, and 4 = severe psoriasis (the worst assessment on this scale). Higher scores in the IGA indicate a worse outcome.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="45"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Null hypotheses were tested at Week 12 (individual M1095 treatment arms would not be different from placebo with respect to achievement of IGA scores of 0 or 1). The primary analysis was based on the intent-to-treat (ITT) population using a non-responder imputation (NRI) for missing values. Primary treatment comparisons versus placebo were made with the two-sided Cochran-Mantel-Haenszel (CMH) test stratified by actual prior biologic use (yes/no) and body weight (&lt;=90; &gt;90kg).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A sample size of 300 subjects has 99% power to detect a statistically significant difference between any treatment arm and placebo in the IGA score of 0 or 1 rate at Week 12, with a two-sided, unadjusted type I error of 0.05. Calculations assume IGA score 0 or 1 rates &gt;88% for study drug and &lt;=7% for placebo.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <other_analysis_desc>At Week 12, none (0.0% [95% CI 0.0-6.8]) of the 52 participants in the placebo group had an IGA score of 0 or 1 versus 25 (48.1% [34.0-62.4], p&lt;0.0001) of 52 participants in the M1095 30mg treatment group. Odds ratio could not be calculated due to the placebo group containing no responders.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Null hypotheses were tested at Week 12 (individual M1095 treatment arms would not be different from placebo with respect to achievement of IGA scores of 0 or 1). The primary analysis was based on the intent-to-treat (ITT) population using a non-responder imputation (NRI) for missing values. Primary treatment comparisons versus placebo were made with the two-sided Cochran-Mantel-Haenszel (CMH) test stratified by actual prior biologic use (yes/no) and body weight (&lt;=90; &gt;90kg).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A sample size of 300 subjects has 99% power to detect a statistically significant difference between any treatment arm and placebo in the IGA score of 0 or 1 rate at Week 12, with a two-sided, unadjusted type I error of 0.05. Calculations assume IGA score 0 or 1 rates &gt;88% for study drug and &lt;=7% for placebo.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <other_analysis_desc>At Week 12, none (0.0% [95% CI 0.0-6.8]) of the 52 participants in the placebo group had an IGA score of 0 or 1 versus 44 (84.6% [71.9-93.1], p&lt;0.0001) of 52 participants in the M1095 60mg treatment group. Odds ratio could not be calculated due to the placebo group containing no responders.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Null hypotheses were tested at Week 12 (individual M1095 treatment arms would not be different from placebo with respect to achievement of IGA scores of 0 or 1). The primary analysis was based on the intent-to-treat (ITT) population using a non-responder imputation (NRI) for missing values. Primary treatment comparisons versus placebo were made with the two-sided Cochran-Mantel-Haenszel (CMH) test stratified by actual prior biologic use (yes/no) and body weight (&lt;=90; &gt;90kg).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A sample size of 300 subjects has 99% power to detect a statistically significant difference between any treatment arm and placebo in the IGA score of 0 or 1 rate at Week 12, with a two-sided, unadjusted type I error of 0.05. Calculations assume IGA score 0 or 1 rates &gt;88% for study drug and &lt;=7% for placebo.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <other_analysis_desc>At Week 12, none (0.0% [95% CI 0.0-6.8]) of the 52 participants in the placebo group had an IGA score of 0 or 1 versus 41 (77.4% [63.8-87.7], p&lt;0.0001) of 53 participants in the M1095 120mg normal load treatment group. Odds ratio could not be calculated due to the placebo group containing no responders.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Null hypotheses were tested at Week 12 (individual M1095 treatment arms would not be different from placebo with respect to achievement of IGA scores of 0 or 1). The primary analysis was based on the intent-to-treat (ITT) population using a non-responder imputation (NRI) for missing values. Primary treatment comparisons versus placebo were made with the two-sided Cochran-Mantel-Haenszel (CMH) test stratified by actual prior biologic use (yes/no) and body weight (&lt;=90; &gt;90kg).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A sample size of 300 subjects has 99% power to detect a statistically significant difference between any treatment arm and placebo in the IGA score of 0 or 1 rate at Week 12, with a two-sided, unadjusted type I error of 0.05. Calculations assume IGA score 0 or 1 rates &gt;88% for study drug and &lt;=7% for placebo.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <other_analysis_desc>At Week 12, none (0.0% [95% CI 0.0-6.8]) of the 52 participants in the placebo group had an IGA score of 0 or 1 versus 45 (88.2% [76.1-95.6], p&lt;0.0001) of 51 participants in the M1095 120mg augmented load treatment group. Odds ratio could not be calculated due to the placebo group containing no responders.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Null hypotheses were tested at Week 12 (individual M1095 treatment arms would not be different from placebo with respect to achievement of IGA scores of 0 or 1). The primary analysis was based on the intent-to-treat (ITT) population using a non-responder imputation (NRI) for missing values. Primary treatment comparisons versus placebo were made with the two-sided Cochran-Mantel-Haenszel (CMH) test stratified by actual prior biologic use (yes/no) and body weight (&lt;=90; &gt;90kg).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A sample size of 300 subjects has 99% power to detect a statistically significant difference between any treatment arm and placebo in the IGA score of 0 or 1 rate at Week 12, with a two-sided, unadjusted type I error of 0.05. Calculations assume IGA score 0 or 1 rates &gt;88% for study drug and &lt;=7% for placebo.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <other_analysis_desc>At Week 12, none (0.0% [95% CI 0.0-6.8]) of the 52 participants in the placebo group had an IGA score of 0 or 1 versus 41 (77.4% [63.8-87.7], p&lt;0.0001) of 53 participants in the secukinumab 300mg treatment group. Odds ratio could not be calculated due to the placebo group containing no responders.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Psoriasis Area and Severity Index (PASI) Reduction of 100% (i.e. Clear of Psoriasis)</title>
        <description>PASI 100, i.e. a subject's psoriasis has completely cleared at Week 12, compared to baseline.</description>
        <time_frame>Week 12, as compared to Week 0 (baseline)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>M1095 30mg</title>
            <description>M1095, 30 mg, given at Week 0, 2, 4, and 8 weeks.&#xD;
M1095: M1095 is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.</description>
          </group>
          <group group_id="O2">
            <title>M1095 60mg</title>
            <description>M1095, 60 mg, given at Week 0, 2, 4, and 8 weeks.&#xD;
M1095: M1095 is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.</description>
          </group>
          <group group_id="O3">
            <title>M1095 120mg - Regimen 1</title>
            <description>M1095, 120 mg, given at Week 0, 2, 4, and 8 weeks.&#xD;
M1095: M1095 is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.</description>
          </group>
          <group group_id="O4">
            <title>M1095 120mg - Regimen 2</title>
            <description>M1095, 120 mg, given at Week 0, 2, 4, 6, 8, and 10 weeks.&#xD;
M1095: M1095 is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.</description>
          </group>
          <group group_id="O5">
            <title>Placebo / M1095 120mg</title>
            <description>Placebo, given at Week 0, 1, 2, 3, 4, 6, 8 and 10 weeks.&#xD;
Placebo: Placebo contains no active drug.</description>
          </group>
          <group group_id="O6">
            <title>Secukinumab</title>
            <description>Secukinumab, 300mg, given at Week 0, 1, 2, 3, 4, and 8 weeks.&#xD;
Secukinumab: Secukinumab is a human immunoglobulin G1 (IgG1) monoclonal antibody that selectively binds IL-17A.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Psoriasis Area and Severity Index (PASI) Reduction of 100% (i.e. Clear of Psoriasis)</title>
          <description>PASI 100, i.e. a subject's psoriasis has completely cleared at Week 12, compared to baseline.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Psoriasis Area and Severity Index (PASI) Reduction of 90% (i.e. a 90% Improvement in Psoriasis)</title>
        <description>PASI 90, i.e. a subject's psoriasis has cleared by 90% at Week 12, compared to baseline</description>
        <time_frame>Week 12, as compared to baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>M1095 30mg</title>
            <description>M1095, 30 mg, given at Week 0, 2, 4, and 8 weeks.&#xD;
M1095: M1095 is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.</description>
          </group>
          <group group_id="O2">
            <title>M1095 60mg</title>
            <description>M1095, 60 mg, given at Week 0, 2, 4, and 8 weeks.&#xD;
M1095: M1095 is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.</description>
          </group>
          <group group_id="O3">
            <title>M1095 120mg - Regimen 1</title>
            <description>M1095, 120 mg, given at Week 0, 2, 4, and 8 weeks.&#xD;
M1095: M1095 is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.</description>
          </group>
          <group group_id="O4">
            <title>M1095 120mg - Regimen 2</title>
            <description>M1095, 120 mg, given at Week 0, 2, 4, 6, 8, and 10 weeks.&#xD;
M1095: M1095 is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.</description>
          </group>
          <group group_id="O5">
            <title>Placebo / M1095 120mg</title>
            <description>Placebo, given at Week 0, 1, 2, 3, 4, 6, 8 and 10 weeks.&#xD;
Placebo: Placebo contains no active drug.</description>
          </group>
          <group group_id="O6">
            <title>Secukinumab</title>
            <description>Secukinumab, 300mg, given at Week 0, 1, 2, 3, 4, and 8 weeks.&#xD;
Secukinumab: Secukinumab is a human immunoglobulin G1 (IgG1) monoclonal antibody that selectively binds IL-17A.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Psoriasis Area and Severity Index (PASI) Reduction of 90% (i.e. a 90% Improvement in Psoriasis)</title>
          <description>PASI 90, i.e. a subject's psoriasis has cleared by 90% at Week 12, compared to baseline</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="39"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Psoriasis Area and Severity Index (PASI) Reduction of 75% (i.e. a 75% Improvement in Psoriasis)</title>
        <description>PASI 75, i.e. a subject's psoriasis has cleared by 75% at Week 12, compared to baseline</description>
        <time_frame>Week 12, as compared to Week 0 (baseline)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>M1095 30mg</title>
            <description>M1095, 30 mg, given at Week 0, 2, 4, and 8 weeks.&#xD;
M1095: M1095 is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.</description>
          </group>
          <group group_id="O2">
            <title>M1095 60mg</title>
            <description>M1095, 60 mg, given at Week 0, 2, 4, and 8 weeks.&#xD;
M1095: M1095 is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.</description>
          </group>
          <group group_id="O3">
            <title>M1095 120mg - Regimen 1</title>
            <description>M1095, 120 mg, given at Week 0, 2, 4, and 8 weeks.&#xD;
M1095: M1095 is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.</description>
          </group>
          <group group_id="O4">
            <title>M1095 120mg - Regimen 2</title>
            <description>M1095, 120 mg, given at Week 0, 2, 4, 6, 8, and 10 weeks.&#xD;
M1095: M1095 is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.</description>
          </group>
          <group group_id="O5">
            <title>Placebo / M1095 120mg</title>
            <description>Placebo, given at Week 0, 1, 2, 3, 4, 6, 8 and 10 weeks.&#xD;
Placebo: Placebo contains no active drug.</description>
          </group>
          <group group_id="O6">
            <title>Secukinumab</title>
            <description>Secukinumab, 300mg, given at Week 0, 1, 2, 3, 4, and 8 weeks.&#xD;
Secukinumab: Secukinumab is a human immunoglobulin G1 (IgG1) monoclonal antibody that selectively binds IL-17A.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Psoriasis Area and Severity Index (PASI) Reduction of 75% (i.e. a 75% Improvement in Psoriasis)</title>
          <description>PASI 75, i.e. a subject's psoriasis has cleared by 75% at Week 12, compared to baseline</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="45"/>
                    <measurement group_id="O4" value="46"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the signing of the informed consent form i.e. the start of the screening period (Week -4) through to the end of the study (Week 52).</time_frame>
      <desc>Arms/groups for presentation of adverse event reporting were pre-specified in the Statistical Analysis Plan.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo (Week 0 to Week 12)</title>
          <description>Placebo given at Weeks 0, 2, 4 and 8.&#xD;
Placebo: Placebo contains no active drug.</description>
        </group>
        <group group_id="E2">
          <title>M1095 30mg (Week 0 to Week 12)</title>
          <description>M1095, 30mg, given at Weeks 0, 2, 4 and 8.&#xD;
M1095: M1095 is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.</description>
        </group>
        <group group_id="E3">
          <title>M1095 60 mg (Week 0 to Week 12)</title>
          <description>M1095, 60mg, given at Weeks 0, 2, 4 and 8.&#xD;
M1095 is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.</description>
        </group>
        <group group_id="E4">
          <title>M1095 120mg - Normal Load Group (Week 0 to Week 12)</title>
          <description>M1095, 120 mg, given at Weeks 0, 2, 4 and 8.&#xD;
M1095: M1095 is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.</description>
        </group>
        <group group_id="E5">
          <title>M1095 120mg - Augmented Load Group (Week 0 to Week 12)</title>
          <description>M1095, 120 mg, given at Weeks 0, 2, 4, 6, 8 and 10.&#xD;
M1095: M1095 is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.</description>
        </group>
        <group group_id="E6">
          <title>Secukinumab (Week 0 to Week 12)</title>
          <description>Secukinumab, 300mg, given at Weeks 0, 1, 2, 3, 4 and 8.&#xD;
Secukinumab: Secukinumab is a human immunoglobulin G1 (IgG1) monoclonal antibody that selectively binds IL-17A.</description>
        </group>
        <group group_id="E7">
          <title>M1095 - All Participants (Week 0 to Week 12 )</title>
          <description>All participants receiving M1095, 30mg, 60mg, or 120mg from Week 0 to Week 12.&#xD;
M1095: M1095 is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.</description>
        </group>
        <group group_id="E8">
          <title>M1095 - All Participants (Week 12 to Week 52)</title>
          <description>All participants receiving M1095, 30mg, 60mg, or 120mg from Week 12 to Week 44, including subjects randomised to placebo, who received M1095 120mg from Weeks 12, 14, 16, 20, etc.&#xD;
M1095: M1095 is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.</description>
        </group>
        <group group_id="E9">
          <title>Secukinumab (Week 12 to Week 52)</title>
          <description>Secukinumab, 300mg, given at Weeks 12, 16, 20 and every 4 weeks to week 44)&#xD;
Secukinumab: Secukinumab is a human immunoglobulin G1 (IgG1) monoclonal antibody that selectively binds IL-17A.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (22.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="208"/>
                <counts group_id="E8" subjects_affected="12" subjects_at_risk="251"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="251"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Optic ischaemic neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Salivary gland calculus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Infectious pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Oropharyngeal candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuroglycopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (22.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="62" subjects_at_risk="208"/>
                <counts group_id="E8" subjects_affected="57" subjects_at_risk="251"/>
                <counts group_id="E9" subjects_affected="16" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="28" subjects_at_risk="208"/>
                <counts group_id="E8" subjects_affected="26" subjects_at_risk="251"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="208"/>
                <counts group_id="E8" subjects_affected="12" subjects_at_risk="251"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="208"/>
                <counts group_id="E8" subjects_affected="13" subjects_at_risk="251"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="208"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="251"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="208"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="251"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="14" subjects_at_risk="208"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="251"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="208"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="251"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Avillion LLP</organization>
      <phone>+44 (0)203 764 9530</phone>
      <email>avillion@avillionllp.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

